Monopar Therapeutics
Update in progressMNPR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Monopar Therapeutics Inc. is a clinical‑stage biopharmaceutical company focused on cancer therapeutics in the United States. Its assets include ALXN1840, an oral, once‑daily medicine under license with Alexion for Wilson disease; MNPR‑101, a humanized monoclonal antibody conjugated to radioisotopes for urokinase plasminogen activator receptor–expressing solid tumors; MNPR‑101‑Zr for zirconium‑89 imaging; and MNPR‑101‑Lu, a Phase 1a actinium‑225 radiotherapeutic. It collaborates with NorthStar and Excel Diagnostics for MNPR‑101‑Zr and MNPR‑101‑Lu, and is Wilmette, Illinois, 2014.
Company score
- Sentiment
- 0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section